AIM ImmunoTech Inc. entered into a securities purchase agreement on June 9, 2026, to conduct a registered direct offering of 2,554,119 shares of common stock at $0.5189 per share, expected to raise approximately $1.3 million. The company also conducted a concurrent private placement of 771,503 shares, pre-funded warrants, and Class J warrants, which could potentially provide an additional $5.3 million in gross proceeds. AIM ImmunoTech Inc. is a biotechnology company focused on developing immune-based therapies.
